A Study of Gemcitabine, Paclitaxel, Motixafortide, and Cemiplimab in People With Pancreatic Cancer

Full Title

Chemo4METPANC: A Phase 2 study with combination CHEmotherapy (Gemcitabine and Nab-Paclitaxel),cheMOkine (C-X-C) motif receptor 4 inhibitor (Motixafortide), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naïve PANCreas adenocarcinoma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Michael May’s office at 914-367-7276.

Protocol
26-149
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Michael May
Co-Investigators
Eileen M. O'Reilly
Diseases
Hepatobiliary › Pancreatic Cancer
Upper Gastrointestinal › Pancreatic Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT04543071
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description